Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SLNO, REPL, MDGL, CMPS, ATAI, and represent 56.00% of Ally Bridge Group's stock portfolio.
- Added to shares of these 10 stocks: SLNO (+$25M), MDGL (+$15M), REPL (+$13M), ATAI (+$12M), ASND (+$10M), TSHA (+$6.2M), AMLX (+$5.9M), EPRX (+$5.4M), ARQT, CMPS.
- Started 9 new stock positions in MLTX, AVTX, ARQT, MDGL, ATAI, ASND, TSHA, EPRX, AMLX.
- Reduced shares in these 10 stocks: VRNA (-$15M), LENZ (-$7.8M), MRUS (-$7.4M), Ultragenyx Pharmaceutical In (-$5.8M), ELVN (-$5.6M), ORIC, INSM, GERN, MNMD, CNTA.
- Sold out of its positions in RNA, CNTA, ELVN, GERN, INSM, KRRO, LXEO, ORIC, Ultragenyx Pharmaceutical In, VRNA. MRUS.
- Ally Bridge Group was a net buyer of stock by $32M.
- Ally Bridge Group has $164M in assets under management (AUM), dropping by 36.64%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 22 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Soleno Therapeutics (SLNO) | 22.7 | $37M | +208% | 553k | 67.60 |
|
| Replimune Group Call Option (REPL) | 9.2 | $15M | +581% | 3.6M | 4.19 |
|
| Madrigal Pharmaceuticals (MDGL) | 9.1 | $15M | NEW | 33k | 458.66 |
|
| Compass Pathways Sponsored Ads (CMPS) | 7.6 | $12M | +46% | 2.2M | 5.73 |
|
| Atai Beckley Nv SHS (ATAI) | 7.4 | $12M | NEW | 2.3M | 5.29 |
|
| Ascendis Pharma A/s - Sponsored Adr (ASND) | 6.2 | $10M | NEW | 51k | 198.81 |
|
| Lenz Therapeutics (LENZ) | 5.0 | $8.2M | -48% | 175k | 46.58 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 3.8 | $6.2M | NEW | 1.9M | 3.27 |
|
| Amylyx Pharmaceuticals (AMLX) | 3.6 | $5.9M | NEW | 437k | 13.59 |
|
| Eupraxia Pharmaceuticals (EPRX) | 3.3 | $5.4M | NEW | 915k | 5.90 |
|
| Praxis Precision Medicines I Com New Call Option (PRAX) | 3.2 | $5.3M | +23% | 100k | 53.00 |
|
| Monopar Therapeutics Com New (MNPR) | 3.2 | $5.3M | +86% | 65k | 81.67 |
|
| Arcutis Biotherapeutics (ARQT) | 2.7 | $4.4M | NEW | 233k | 18.85 |
|
| Mind Medicine Mindmed Com New (MNMD) | 2.6 | $4.3M | -50% | 361k | 11.79 |
|
| Tarsus Pharmaceuticals (TARS) | 2.6 | $4.2M | -41% | 71k | 59.43 |
|
| Solid Biosciences Com New (SLDB) | 2.1 | $3.4M | -24% | 549k | 6.17 |
|
| Promis Neurosciences Com New (PMN) | 1.6 | $2.6M | +367% | 6.2M | 0.42 |
|
| Avalo Therapeutics Com New (AVTX) | 1.4 | $2.3M | NEW | 178k | 12.71 |
|
| Tectonic Therapeutic (TECX) | 1.3 | $2.2M | -15% | 139k | 15.69 |
|
| Aadi Bioscience (WHWK) | 0.9 | $1.6M | 818k | 1.90 |
|
|
| Moonlake Immunotherapeutics Class A Ord Call Option (MLTX) | 0.3 | $495k | NEW | 69k | 7.17 |
|
| Atyr Pharma Com New Call Option (ATYR) | 0.3 | $433k | +108% | 600k | 0.72 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2025 Q3 filed Nov. 14, 2025
- Ally Bridge Group 2025 Q2 filed Aug. 14, 2025
- Ally Bridge Group 2025 Q1 filed May 15, 2025
- Ally Bridge Group 2024 Q4 filed Feb. 14, 2025
- Ally Bridge Group 2024 Q3 filed Nov. 14, 2024
- Ally Bridge Group 2024 Q2 filed Aug. 14, 2024
- Ally Bridge Group 2024 Q1 filed May 15, 2024
- Ally Bridge Group 2023 Q4 filed Feb. 14, 2024
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022
- Ally Bridge Group 2022 Q2 filed Aug. 15, 2022
- Ally Bridge Group 2022 Q1 filed May 16, 2022
- Ally Bridge Group 2021 Q4 filed Feb. 14, 2022